Antonio Mazzeo

Antonio Mazzeo is the Executive Director, Business Development at Angelini Pharma. Prior to joining Angelini, Antonio was with Nomura from June 2010 to May 2015 as part of the M&A Healthcare team. During their time at Nomura, Antonio was responsible for developing extensive coverage of healthcare businesses, conducting financial valuations and developing Buy side/sell side ideas for several clients across the industry. Antonio also led a team through the development of confidential information memoranda and management presentations, managed day to day interaction with potential buyers including negotiation and evaluation of bids, and conducted in-depth operating and financial diligence. Some of Antonio's key projects include advising Astorg and Montagu in the acquisition of IVD specialty player Sebia, advising PHW Group in the sale of its Animal Health division to Eli Lilly, and advising Grifols in the acquisition of IVD unit of Novartis.

Mazzeo has an MBA in Economics from SDA Bocconi, an executive program in finance and competitive strategy from The University of Chicago Booth School of Business, and a master of science in management engineering from Università degli Studi di Napoli Federico II.

Their manager is Pierluigi Antonelli, CEO. Some of their coworkers include Daniela Poggio - Executive Director, Global Communications, Fabrizio Caranci - Executive Director, Global Digital Medicines, and Gabriele Ghirlanda - Global Chief, Access & Value.